TNFA - TNF Pharmaceuticals, Inc.
0.1926
-0.006 -3.063%
Share volume: 761,025
Last Updated: 05-07-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$0.20
-0.01
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-15-2024 | 08-19-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | |||
| Operating expenses | 2.267 M | 1.421 M | 1.812 M | |
| Selling general and admin | 1.068 M | 1.020 M | 1.104 M | |
| Research and development | 1.199 M | 401.104 K | 707.747 K | |
| Total expenses | 2.785 M | 3.370 M | 1.826 M | |
| 21.01% | -45.82% | |||
| Operating income | -2.785 M | -3.370 M | -1.826 M | |
| Ebit | -9.818 M | -9.587 M | -2.093 M | |
| Pretax income | -9.800 M | -9.566 M | -1.929 M | |
| -2.39% | -79.83% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -9.800 M | -9.566 M | -1.929 M | |
| 2.39% | 79.83% |
